This product is DEA controlled substance and is not available for sale! Cyclazodone is a novel and potent stimulant agent

GSK3395879 is a novel, potent, selective and orally bioavailable transient receptor potential vanilloid-4 (TRPV4) antagonist with an IC50 of 1 nM for hTRPV4. It was developed by modification of a previously reported TRPV4 inhibitor. Several core-structure modifications were identified that improved TRPV4 activity by increasing structural rigidity and reducing the entropic energy penalty upon binding […]

Fosravuconazole (formerly known as E-1224, BEF-1224, and BMS-379224) is an azole-based antifungal agent that can be potentially used for the treatment of fungal infections. It is a prodrug of ravuconazole with improved water solubility. The phosphonooxymethyl ether fosravuconazole was prepared from ravuconazole and bis-tert-butyl chloromethylphosphate. Fosravuconazole was highly soluble in water and converted to the […]

GSK376501A is a novel,, potent and selective peroxisome proliferator-activated receptor gamma (PPARγ) modulator that has the potential for the treatment of type 2 diabetes mellitus.

Tofimilast (also known as CP-325366) is a novel and potent PDE4 (phosphodiesterase 4) inhibitor. It was developed by Pfizer and can be potentially used for the treatment of asthma and chronic obstructive pulmonary disease (COPD).

Enantiomer of Sofosbuvir is the isomer/enantiomer of Sofosbuvir (also known as PSI-7977, GS-7977; trade names Sovaldi and Virunon) is a HCV NS5B polymerase inhibitor that is used for the treatment of chronic hepatitis C virus (HCV) infection. Sofosbuvir acts by inhibiting the RNA polymerase that the hepatitis C virus uses to replicate its RNA. It […]

KD-3010 is a potent, orally bioactive, and selective agonist of peroxisome proliferator-activated receptor delta (PPARδ) that can be potentially used for the treatment of diabetes and obesity. Peroxisome proliferator-activated receptor delta (PPARδ), a member of the nuclear receptor family, is emerging as a key metabolic regulator with pleiotropic actions on various tissues including fat, skeletal […]

Cariprazine (formerly known as MP-214 and RGH-188) is a novel and potent antipsychotic drug candidate that is in late-stage clinical development for the treatment of schizophrenia, as well as for bipolar disorder (manic/mixed and depressive episodes), and as an adjunctive agent for the treatment of major depressive disorder. Cariprazine is a dopamine D3-preferring D3/D2 receptor […]

GSK3186899 (also known as DDD-853651) is a novel and potent inhibitor of cdc-2-related kinase 12 (CRK12), with an EC50 of 1.4 μM for L. donovani in an intra-macrophage assay. Visceral leishmaniasis causes considerable mortality and morbidity in many parts of the world. There is an urgent need for the development of new, effective treatments for […]

BMS-830216 is a prodrug of BMS-819881 which is a novel and potent antagonist of MCHR1 (Melanin concentrating hormone receptor 1) with minimal hERG activity. It binds to rat MCHR1 with a Ki of 7 nM and is also selective for CYP3A4 activity with an EC50 of 13 μM. BMS-819881 has the potential to be used […]